News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

A5 Labs Provides Operational Update


1/19/2011 9:47:52 AM

MONTREAL, QUEBEC--(Marketwire - January 19, 2011) - A5 Laboratories Inc. (OTCBB: AFLB) is pleased to announce successful completion of laboratory scale manufacturing of porcine interferon.

Richard Azani, Chief Executive Officer of A5 Laboratories Inc., stated: "We view the manufacturing of porcine interferon as a major milestone in our business plan and we are now prepared to enter the next phase. The porcine interferon has been produced according to our proprietary technology."

"Successful manufacturing of porcine interferon is the first step toward manufacturing of interferon for the veterinary field. The same production technology applied to other cell lines would allow us to obtain interferon for given species, including but not limited to bovine, equine, poultry, among many more. Our next target would be bovine interferon, continued Mr. Azani.

About A5 Laboratories Inc

A5 Laboratories is a specialty biotechnology company engaged in the development and marketing of novel immun therapeutic applications of a natural Gamma - Interferon (nG-IFN). Such applications include the diagnostic, the prevention and the treatment of various animal and human diseases.

The pathologies targeted by Cytokines Biotech's nG-INF include viral, bacterial, fungal and parasitic infections as well as various auto-immune conditions and cancer, and emphasis will be initially put on opportunistic infections in HIV patients, antibiotic-resistant bacteria and some rare types of cancers.

SAFE HARBOR STATEMENT

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to A5, and specifically the production and testing of A5's interferon product, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of A5's products, the competitive environment within the industry, the ability of A5 to continue to expand its operations, the level of costs incurred in connection with A5's expansion efforts, economic conditions in the industry and the financial strength of A5's customers and suppliers. A5 does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.


Contacts:
Investor Relations Contact
Andrew Barwicki
516-662-9461
andrew@barwicki.com


Read at BioSpace.com

comments powered by Disqus
A5 Labs
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES